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The author declares no competing financial interests. also had multiple members with various malignancies, including two members with uveal melanoma in family L. Somatic alterations in the familial mesothelioma tumors indicated biallelic inactivation of BAP1. Testa et al. 4 also sequenced BAP1 in germline DNA from 26 sporadic mesothelioma cases and uncovered two inactivating frameshift mutations in individuals who were subsequently found to have had earlier diagnoses of uveal melanoma. Given the rarity of both uveal melanoma and mesothelioma in the United States, the authors concluded that it was extremely unlikely for these two malignancies to have occurred in the same individuals by chance.
BAP1 mutations and other cancers
Beside uveal melanoma, mesothelioma and the distinct melanocytic tumors, numerous additional tumors were observed in the families 3, 4 . Specifically, several cancers, including cutaneous epithelioid nevi to atypical melanocytic proliferations with features that overlapped with cutaneous melanoma. Both families had one member with uveal melanoma, and family 2 had multiple members with cutaneous melanoma. Affected family members had many (5 to >50) of the clinically and histopathologically distinct melanocytic tumors, whereas there were few melanomas, suggesting that the risk of malignant potential in individual tumors was low. Examination of a subset of the familial melanocytic tumors showed that the majority of tumors showed biallelic inactivation of BAP1 by various somatic alterations.
Testa et al. 4 discovered co-segregating germline mutations in BAP1 in two families (L and W) with five or more members with mesothelioma. The families had modest levels of asbestos exposure from having lived in asbestos-containing houses but did not have occupational asbestos exposure. The families BAP1 is a tumor suppressor gene located on chromosome 3p21 in a region that shows loss or deletions in numerous cancers, including lung and breast cancers as well as uveal melanoma and mesothelioma. Two recent studies reported high frequencies of somatic mutations in BAP1 in uveal melanoma 1 and mesothelioma 2 . Harbour et al. 1 found inactivating somatic mutations of BAP1 in 47% (28/60) of uveal melanomas (Table 1) , with a much higher frequency (27/34, 79%) in metastasizing uveal melanomas. In addition, one tumor had a germline frameshift mutation, suggesting that this variant was a susceptibility allele. Bott et al. 2 identified somatic inactivating BAP1 mutations in 23% (12/53) of a discovery set of malignant pleural mesotheliomas, half of them from individuals who reported asbestos exposure, and in 18% (12/68) of an independent set of malignant pleural mesotheliomas. In this issue, Wiesner, Bastian, Speicher and colleagues 3 and Testa, Carbone and colleagues 4 provide further links between BAP1, uveal melanoma and mesothelioma by identifying germline BAP1 mutations in two putatively distinct cancer-related syndromes characterized predominantly by melanocytic tumors or mesothelioma, respectively, along with uveal melanoma in both cases.
Two new cancer-related syndromes?
Wiesner et al. 3 identified co-segregating germline mutations in BAP1 in two families (1 and 2) with multiple members with melanocytic tumors that ranged histopathologically from Germline BAP1 mutations and tumor susceptibility
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Two new studies describe germline mutations in BAP1 in putatively dissimilar cancer-related syndromes. The spectrum of neoplasms associated with these germline mutations suggest that BaP1 has an important tumor suppressor function in multiple tissues. was a key event in uveal melanoma metastasis. The current studies suggest a potentially more complex scenario that may depend on various combinations of the tissue of origin, environmental exposures, functional consequences of the BAP1 mutations and mechanisms of inactivation of the second BAP1 allele. BAP1 (ubiquitin carboxy-terminal hydrolase/ BRCA1-associated protein 1), a 729-aminoacid, nuclearly localized enzyme, was originally identified as a ubiquitin hydrolase that binds to the RING finger domain of BRCA1 (refs. 7,11) . BAP1 contains numerous functional domains, including the ubiquitin C-terminal hydrolase (UCH) domain, a host cell factor-1 (HCF-1) binding domain and binding domains for BRCA1 and BARD1. BAP1 has been functionally implicated in numerous biologic processes, including chromatin dynamics, DNA damage response, and regulation of the cell cycle and cell growth 1, 2, 7, [11] [12] [13] [14] [15] . Given this functional complexity, different germ line mutations in BAP1 may predispose to divergent tumor types.
Future directions
These studies raise several provocative questions. Are these disorders two distinct syndromes or a single syndrome with a wide phenotypic range? For what tumor types do germline BAP1 mutations increase susceptibility? What role do exposures (to, for example, asbestos or ultraviolet radiation) have on the melanoma (n = 3), non-melanoma skin (n = 2), ovarian (n = 1), breast (n = 1), renal (n = 1) and pancreatic (n = 1) cancer, occurred in family members who inherited their family's inactivating BAP1 mutation. Assessment of whether these cancers are part of the spectrum of tumors related to germline BAP1 mutations will require additional study.
Data from COSMIC (Catalogue Of Somatic Mutations In Cancer) 5, 6 reveal low frequencies of somatic BAP1 mutations in several of the tumors observed, including breast (0.4%), ovarian (3.4%) and pancreatic (0.0%) cancer ( Table 1) . In addition, Wiesner et al. 3 showed that 5% (3/60) of primary melanomas originating from acral skin (n = 15), mucosa (n = 15) or skin with (n = 15) or without (n = 15) chronic sun damage had somatic BAP1 mutations. Finally, lung cancers, which were one of the first categories of cancers originally reported to have somatic BAP1 mutations 7 , also had very few somatic mutations (0.6%) 5, 6 , suggesting that another gene in the 3p21 region may be implicated in some of the cancers that show losses in this region [8] [9] [10] . Alternatively, a different mechanism of BAP1 inactivation may be involved. In contrast to the low frequency of somatic mutations for the tumor types described above, 44% (41/93) of uveal melanomas and 20% (28/139) of sporadic mesotheliomas had somatic mutations of BAP1 (Table 1) [1] [2] [3] [4] . For most of the tumors evaluated, BAP1 showed biallelic loss. Harbour et al. 1 hypothesized that biallelic loss of BAP1 Sahar Mansour 3 and colleagues report GATA2 mutations in patients with Emberger syndrome, which is characterized by severe lymphedema in addition to predisposition to MDS and AML 4 . GATA2 mutations have also been described very recently in two almost identical syndromes with a tendency to develop MDS and AML: monocytopenia and mycobacterial infection (MonoMAC) syndrome 5 and a syndrome associated with defects in dendritic cells, monocytes, and B and NK lymphoid cells (DCML) 6 . Despite the differences in accessory hematopoietic defects, the mutations described in these reports are very similar, and in some cases identical (Fig. 1). predisposition to MDS and AML have been described. Mutations in the genes encoding two important hematopoietic transcription factors, RUNX1 and CEBPA 1 , have been identified in these familial disorders. Both disorders are associated with distinct hematological defects before the onset of MDS and AML.
Two reports in this issue 2, 3 demonstrate that mutations in another hematopoietic transcription factor, GATA2, are found in families with predisposition to MDS and AML. Hamish Scott and colleagues 2 describe GATA2 mutations in four different families that show predisposition to MDS and AML but lack any preceding hematopoietic abnormalities.
Normal hematopoiesis is tightly regulated by a series of transcription factors. Consequently, it is not surprising that the abrogation of specific transcription factor activity results in impaired differentiation of blood cells and the development of related diseases, such as MDS and AML. Although MDS and AML are mostly sporadic, rare familial disorders involving a GATA2 mutations lead to Mds and aML
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several new studies report mutations in the gene GATA2 in three different familial syndromes characterized by predisposition to myelodysplastic syndrome (Mds) and acute myeloid leukemia (aML). Before the onset of Mds and aML, patients with similar GATA2 mutations had distinct hematological abnormalities.
